| Insider | Role | Shares | Value | Buys | Sells |
|---|---|---|---|---|---|
| Date | Ticker | Insider | Role | Type | Shares | Price | Value | Chg% | SEC |
|---|---|---|---|---|---|---|---|---|---|
| Insider | Role | Shares | Value | Buys | Sells |
|---|---|---|---|---|---|
| Date | Ticker | Insider | Role | Type | Shares | Price | Value | Chg% | SEC |
|---|---|---|---|---|---|---|---|---|---|
Classified under Biotechnology (Health Care sector), ATOS's insider flows are most useful compared with peers in the same group.
| Role | Insider | Shares | Value | 30d |
|---|---|---|---|---|
| CEO | 339.1K | - | - | |
| CFO | 63.0K | - | - | |
| Dir | 11.7K | - | - | |
| Dir | 10.7K | - | - | |
| Dir | 10.0K | - | - |
Buys and sells only
| Date | Insider | Role | Type | Shares | Price | Value | Chg% | 3M | 12M | SEC |
|---|---|---|---|---|---|---|---|---|---|---|
| May 21, 2025 | Quay Steven C | President &CEO | Buy | 11,239 | $0.88 | $9,886.95 | +422.7% | -13.9% | - | |
| Mar 26, 2025 | Remmel H. Lawrence | Director | Buy | 10,000 | $0.70 | $7,000.00 | +3,891% | +18.6% | -54.9% | |
| Apr 10, 2024 | Finn Jonathan | Director | Buy | 25,000 | $1.77 | $44,250.00 | New | -34.3% | -66.3% | |
| Nov 15, 2023 | Weaver Gregory L | Former EVP, CFO, &Director | Sell | 50,000 | $0.65 | $32,500.00 | -99.9% | +48.3% | +109.4% | |
| Jun 20, 2023 | Weaver Gregory L | EVP &CFO | Buy | 50,000 | $0.97 | $48,500.00 | +90,909% | -16.8% | +16.1% | |
| Jul 2, 2021 | Weaver Gregory L | Director | Sale+OE | 107,497 | $5.58 | $599,833.26 | -100% | -39.3% | -81.2% | |
| Nov 15, 2017 | Guse Kyle | CFO, Gen Counsel And Secretary | Buy | 10,000 | $0.34 | $3,369.30 | New | - | - | |
| Apr 17, 2017 | Remmel H. Lawrence | Director | Buy | 2,500 | $0.63 | $1,580.00 | +399.4% | - | - | |
| Apr 1, 2016 | Remmel H. Lawrence | Director | Buy | 1,500 | $0.33 | $495.00 | +16.0% | - | - | |
| Mar 9, 2016 | Quay Steven C | President &CEO | Buy | 15,000 | $0.37 | $5,550.00 | +0.3% | - | - |